It’s official! #SetPointSystem is now FDA approved for the treatment of rheumatoid arthritis (RA) in adults who are not adequately managed by, or who cannot tolerate, existing advanced RA therapies. See the release: https://t.co/wlE2DFjqPY #Rheumatology #RheumTwitter #MedTwitter

We’re honored that the SetPoint System has been named one of @TIME’s Best Inventions of 2025 in Medical & Healthcare. 🏆 Read about it here: https://t.co/RD4wA8eVl4 Please see important safety information at https://t.co/wgUlNYJOwy #TIMEBestInventions #StartActivating #RA

We’re thrilled to see the #SetPointSystem featured on @NPR. The story spotlights Lynn, who found relief after years of debilitating RA pain. Please see important safety information at https://t.co/wgUlNYJOwy https://t.co/jeBP41JeGS

Big news today! @NorthwellHealth is the first health system in the nation to provide the recent FDA-approved #SetPointSystem, implanting its first patient on Aug. 22. Read about it: https://t.co/hV3SarOY5k #SetPointTherapy #RheumatoidArthritis #RheumTwitter #NeuroimmuneModulation

Big ambition takes big investment and audacious leadership -- that's why we're excited to announce today that we've secured $140 million in private financing, and welcomed key new executives to our leadership team and board of directors. Read more:

Controlling the immune system and inflammation through stimulating the vagus nerve. FDA approval of an implant for refractory rheumatoid arthritis that is also being studied for various autoimmune diseases. Front page @nytimes great work by @KevinJTraceyMD @SetPointMed

We're so pleased to see this coverage of the FDA approval of the #SetPointSystem in the @nytimes! Read the full story to learn more about the life-changing power of neuroimmune modulation: https://t.co/KSyNGgxqlW Safety info in bio. #Rheumatology #RheumTwitter #MedTwitter

We were honored to have our national surgical PI @RMarkRichardson present RESET-RA results during the Plenary Session at #AANS25. Data presented highlight SetPoint System’s potential as a first-of-its-kind neuroimmune modulation treatment for RA. #TheSetPointAdvantage

Nice story by @NPR about how neuroimmune modulation is unlocking new possibilities for treating autoimmune diseases like #RA. https://t.co/3vcbgrJ05P #TheSetPointAdvantage The SetPoint System is limited by U.S. law to investigational use only.

We're excited to announce late-breaking data from the RESET-RA study at @ACRheum #ACR24 supporting the SetPoint System's potential as a first-of-its-kind neuroimmune modulation treatment for rheumatoid arthritis (#RA). Learn more in our press release:

Congrats to @SetPointMed for proving the inflammatory reflex benefits patients with RA ! Now onto other autoimmune conditions.... "The study met its primary endpoint with a statistically significant greater proportion of study participants achieving an ACR20 response in the

We're thrilled to announce positive topline results from our RESET-RA clinical study for rheumatoid arthritis (#RA)! The Setpoint System is limited by United States law to investigational use only. Read the full announcement: https://t.co/zVIxmGSo7y #TheSetPointAdvantage

We're happy to share that, following the recent Breakthrough Device Designation, Setpoint's neuroimmune modulation platform for the treatment of MS has now been accepted into the FDA's TAP Pilot! #TheSetPointAdvantage Learn more in our press release:

🎉 Big news incoming: SetPoint’s novel neuroimmune modulation platform received Breakthrough Device Designation from the FDA for multiple sclerosis (MS) treatment! Learn more here: #MSAwarenessWeek #TheSetPointAdvantage https://t.co/ZuihZDbcQq

SetPoint Medical’s co-founder @KevinJTraceyMD spoke with @katiecouric about the innovative field of neuroimmune modulation and our ongoing RESET-RA trial investigating this novel treatment option for RA patients. Check it out:  https://t.co/ZIFO9LiFe6

Thanks to their efforts, and the efforts of many, many more, we continue to make good progress towards wrapping up enrollment in this consequential study this year. Stay tuned! And learn more at https://t.co/pwT905Hem6.

We’re grateful for the dedication and support of our RESET-RA study investigators in South Florida like Dr. Justin Sporrer, as well as Dr. Norman Gaylis, Dr. Guillermo Valenzuela, Dr. Jonathan Greer, Dr. Amiel Tokayer & Dr. Frank Vrionis. https://t.co/MzXQd4NpZ6

Data accumulates targeting the Vagus Nerve inflammatory reflex is giving hope for future options beyond biologics and JAK inhibitors. Is a tipping point approaching ? I really hope so. ⁦@PederOlofsson⁩ ⁦@ACRheum⁩ ⁦@SetPointMed⁩

We're working to prove the value of neuroimmune modulation in #rheumatology, aiming to bring new options for patients. "This is the brand-new field of neuromodulation for the treatment of autoimmune disease,” explains our CMO. Check out the latest buzz:

We are thankful for the support of seasoned investors who possess deep industry knowledge and a passion for improving outcomes for patients with chronic medical conditions, and look forward to furthering our clinical and regulatory goals toward FDA approval of our novel therapy.